Heredity on the Cardiovascular System in Dogs: Mitral Valve Insufficiency and the King Charles Dog
Keywords:
Animal, Cardiovascular diseases, Mitral incompetenceAbstract
This review addresses the genetic basis of cardiovascular disease in dogs, with a particular focus on mitral valve insufficiency (MVI), which is common in the Cavalier King Charles Spaniel breed. MVI is a common degenerative heart disease, especially in small breed dogs, which progresses with age. Genetic predisposition plays a critical role in the pathogenesis of heart disease, and is also important for both early diagnosis and long-term treatment strategies. In the Cavalier King Charles Spaniel breed, polygenic inheritance and loci identification have been reported to be associated with early onset of the disease. In this study, the stages and clinical, echocardiographic and radiologic findings of MVI were detailed in line with the classification systems proposed by ISACH and ACVIM, and also modern diagnostic methods and clinical use of biomarkers were discussed. In addition, the contribution of proteomic research to the understanding of cardiac pathophysiology was emphasized and its relationship with platelet function and coagulation processes in heart failure was evaluated. In conclusion, it is suggested that further studies at the genetic and molecular level will provide innovative approaches in the fields of diagnosis, treatment and preventive medicine in veterinary cardiology practice.
References
Abbott JA. 2016. Acquired valvular disease, in: Tilley LP, Smith FWK, Oyama M, Sleeper MM. (Eds.), Manual of canine and feline cardiology (5th ed.), Saunders Elsevier Inc, St. Louis, Missouri, pp. 111-140.
Amberger C, Chetboul V, Bomassi E, Rougier S, Woehrlé F, Thoulon F, FIRST (First Imidapril Randomized Study) Group. 2004. Comparison of the effects of imidapril and enalapril in a prospective, multicentric, randomized trial in dogs with naturally acquired heart failure. Journal of veterinary cardiology, 6(2): 9-16.
Arcuri G, Valente C, Perini C, Guglielmini C. 2024. Risk factors for atrial fibrillation in the dog: A systematic review. Veterinary sciences, 11: 47.
Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Häggström J, Hamlin R, Keene R, Fuentes VL, Stepien R. 2009. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. Journal of veterinary internal medicine, 23: 1142-1150.
Atkinson KJ, Fine DM, Thombs LA. 2009. Evaluation of pimobendan and n-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. Journal of veterinary internal medicine, 23 (6): 1190-1196.
Baisan RA, de Rosa A, Di Loria A, Vulpe V, Piantedosi D. 2016. Cardiac biomarkers in clinical practice of dog and cat – a review. Human and veterinary medicine, 8(1): 50-58.
Beardow AW, Buchanan JW. 1993. Chronic mitral valve disease in cavalier king charles spaniels: 95 cases (1987-1991). Journal of the American Veterinary Medical Association, 203(7): 1023-1029.
Bilal T. 2011. Köpek ve kedilerde kardiyoloji, first ed. Nobel Tıp Kitabevi, İstanbul.
Borgarelli M, Haggstrom J. 2010. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy. Veterinary clinics of North America: Small animal practice, 40(4):651-663.
Borgarelli, M, Buchanan JW. 2012. Historical review, epidemiology and natural history of degenerative mitral valve disease. Journal of veterinary cardiology, 14: 93-101.
Burkhart JM, Gambaryan S, Watson SP, Jurk K, Walter U, Sickmann A, Heemskerk JW, Zahedi RP. 2014. What can proteomics tell us about platelets? Circulation research, 114: 1204-1219.
Chetboul V, Lefebvre HP, Sampedrano CC, Gouni V, Saponaro FS, Concordet D, Nicolle AP, Pouchelon JL. 2007. Comparative adverse effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: A prospective, controlled, blinded and randomized study. Journal of veterinary internal medicine, 21: 742-753.
Chetboul V, Bussadori C, Madron E. 2016. Clinical Echocardiography of the dog and cat, first ed. Elsevier Masson SAS, St Louis.
Connolly DJ, Magalhaes RJ, Syme HM, et al (2008). Circulating natriuretic peptides in cats with heart disease. Journal of veterinary internal medicine, 22 (1): 96-105.
COVE Study Group. 1995. Controlled clinical evaluation of enalapril in dogs with heart failure: Result of the cooperative veterinary enalapril study group. Journal of veterinary internal medicine, 9: 243-245.
De Madron E. 2015. Assessment and quantification of acquired valvular regurgitation in dogs, in: de Madron E, Chetboul V, Bussadori C. (Eds.), Clinical echocardiography of the dog and cat. Elsevier Inc, St. Louis, pp. 159-180.
do Carmo JLP, Soares GSL, Vieira LS, and Oliveira D. 2024. Atrial natriuretic peptide and cardiovascular diseases in dogs and cats. World's veterinary journal, 14(3): 467-475.
Eriksson A, Hansson K, Häggström J, Järvinen AK, Lord P. 2010. Pulmonary blood volume in mitral regurgitation in cavalier king charles spaniels. Journal of veterinary internal medicine, 24(6): 1393-1399.
Francois AA, Yin X, Oka S, Sadoshima J, Mayr M, Eaton P. 2025. On the utility of immobilized phenylarsine oxide in the study of redox sensitive cardiac proteins. Scientific reports, 15: 15554.
Fries RC, Gordon SG, Saunders AB, Miller MW, Hariu CD, Schaeffer DJ. 2019. Quantitative assessment of two- and three-dimensional transthoracic and two-dimensional transesophageal echocardiography, computed tomography, and magnetic resonance imaging in normal canine hearts. Journal of veterinary cardiology, 21: 79-92.
Fuentes VL, Corcoran B, French A. 2002. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. Journal of veterinary internal medicine, 16: 255-261.
ISACH, International Small Animal Cardiac Health Council. 1994. Recommendations for the diagnosis and treatment of heart failure in small animals. ISACHC Publication, Woodbridge, NJ.
Keene BW, Atkins CE, Bonagura JD, Fox PR, Häggström J, Fuentes VL, Oyama MA, Rush JE, Stepien R, Uechi M. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of veterinary internal medicine, 33: 1127-1140.
Kim SH, Seo KW, Song KH. 2020. An assessment of vertebral left atrial size in relation to the progress of myxomatous mitral valve disease in dogs. Journal of veterinary clinics, 37(1): 9-14.
Kim J K, Park J S, Seo K W, Song K H. 2018. Evaluation of ST2 and NT proBNP as cardiac biomarkers in dogs with chronic mitral valve disease. Journal of veterinary clinics, 35(2): 35-38.
Klein S, Nolte I, Granados-Soler JL, Lietz P, Sehn M, Raue JF, Rohn K, Packeiser EM, Bach JP. 2022. Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease. BMC veterinary research, 18(256): 1-15.
Kocatürk M, Baykal AT, Türkseven Ş, Acıoğlu Ç, Agudelo CF, Yılmaz Z. 2016. Evaluation of serum and ascitic fluid proteomes in dogs with dilated cardiomyopathy. Journal of kafkas university faculty of veterinary medicine, 22: 273-279.
Kvart C, Häggström J, Pedersen HD. 2002. Efficacy of Enalapril for prevention of congestive heart failure in dogs with myxomatous mitral valve disease and asymptomatic mitral regurgitation. Journal of veterinary internal medicine, 16: 80-88.
Lake-Bakaar GA, Johnson EG, Griffiths LG. 2012. Aortic thrombosis in dogs: 31 cases (2000-2010). Journal of the american veterinary medicine association, 241(7): 910-915.
Lee K, Park J S, Seo K W, Song K H. 2018. Evaluation of ST2 and NT proBNP as cardiac biomarkers in dogs with heartworm disease. Korean journal of veterinary service, 41(2): 79-83.
Ljungvall I, Höglund K, Tidholm A, Olsen LH, Borgarelli M, Venge P, Häggström J. 2010. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C reactive protein in dogs. Journal of veterinary internal medicine, 24(1): 153-159.
Locatelli P, Giménez CS, Vega MU, Crottogini A, Belaich MN. 2019. Targeting the cardiomyocyte cell cycle for heart regeneration. Current drug targets, 20(2): 241-254.
Madsen MB, Olsen LH, Häggström J, Höglund K, Ljungvall I, Falk T, Wess G, Stephenson H, Dukes-McEwan J, Chetboul V, Gouni V, Proschowsky HF, Cirera S, Karlskov-Mortensen P, Fredholm M. 2011. Identification of 2 loci associated with development of myxomatous mitral valve disease in cavalier king charles spaniels. Journal of heredity, 102(1): 62-67.
Meurs KM, Friedenberg SG, Williams B, Keene BW, Atkins CE, Adin D, Aona B, DeFrancesco T, Tou S, Mackay T. 2018. Evaluation of genes associated with human myxomatous mitral valve disease in dogs with familial myxomatous mitral valve degeneration. The veterinary journal, 232: 16-19.
Nakayama T, Nishijima Y, Miyamoto M, Hamlin RL. 2007. Effects of 4 classes of cardiovascular drugs on ventricular functionin dogs with mitral regurgitation. Journal of veterinary internal medicine, 21: 445-450.
O’Brien MJ, Beijerink NJ, Wade CM. 2021. Genetics of canine myxomatous mitral valve disease. Animal genetics, 52: 409-421.
Olsen LH, Martinussen T, Pedersen HD. 2003. Early echocardiographic predictors of myxomatous mitral valve disease in Dachshunds. Veterinary record, 152(10): 293-297.
Ontiveros ES, Stern JA. 2021. Genetics of canine subvalvular aortic stenosis (SAS). Canine genetics, 8(1): 4.
Oullet M, Belanger MC, DiFruscia R, Beauchamp G. 2009. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease Journal of veterinary internal medicine, 23: 258-263.
Oyama MA, Fox PR, Rush JE, Rozanski EA, Lesser M. 2008. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. Journal of the American Veterinary Medical Association, 232: 1496-1503.
Oyama MA. 2013. Using cardiac biomarkers in veterinary practice. Veterinary clinics: Small animal practice, 43(6):1261-1272.
Seddigh Nia A, Soylu H, Murat S, İskefli O, Koenhemsi L, Or ME, Gönül R. 2022. Electrocardiographic Changes in cavalier king charles spaniel dogs with mitral valve disease: clinical research. Turkiye Klinikleri journal of veterinary sciences, 13(1): 6-10.
Smith WKF, Tilley LP, Oyama M, Sleeper MM. 2015. Manual of Canine and Feline Cardiology, 5th edition, Saunders press, Missouri.
The IMPROVE Study Group. 1995. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the invasive multicentre prospective veterinary evaluation of enalapril study. Journal of veterinary internal medicine, 9: 234-242.
Tidholm A, Menciotti G, Borgarelli M. 2024. Current use of real-time three-dimensional transthoracic echocardiography in animals. Journal of veterinary cardiology, 51: 97e104.
Wendy WA. 2011. Cardiovascular Disease in Small Animal Medicine. third ed. Manson Publishing, London.
Whitney JC. 1974. Observation on the effect of age on the severity of heart valve lesions in the dogs. Journal of small animal practice, 15(8): 511-522.
Winter RL, Sedacca CD, Adams A, Orton EC. 2012. Aortic thrombosis in dogs: presentation, therapy, and outcome in 26 cases. Journal of veterinary cardiology 14(2): 333-342.
Vereb M, Atkins CE, Adin D, Blondel T, Coffman M, Lee S, Guillot E, Ward JL. 2023. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease. Journal of veterinary internal medicine, 2023: 1-10.
Vezzosi T, Puccinelli C, Citi S, Tognetti R. 2021. Two radiographic methods for assessing left atrial enlargement and cardiac remodeling in dogs with myxomatous mitral valve disease. Journal of veterinary cardiology, 34: 55-63.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 International Journal of Veterinary and Animal Research (IJVAR)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
